T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
about
Immunotherapy for prostate cancer: recent developments and future challengesCloning and characterization of porcine 4Ig-B7-H3: a potent inhibitor of porcine T-cell activationStructure and cancer immunotherapy of the B7 family member B7xExpression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.Role of CD8 T Cell Replicative Senescence in Human Aging and in HIV-mediated ImmunosenescenceHost b7x promotes pulmonary metastasis of breast cancerHHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionSystemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection.Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancerStructure and T cell inhibition properties of B7 family member, B7-H3.Recent advances in immunotherapy for the treatment of prostate cancer.T cell costimulation and coinhibition: genetics and disease.Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins.Prostate cancer vaccines.Antibody therapeutics for treating prostate cancer: where are we now and what comes next?Analysis of the interplay between methylation and expression reveals its potential role in cancer aetiology.PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer.HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.B7x and myeloid-derived suppressor cells in the tumor microenvironment: A tale of two cities.PD-L1 in immune-escape of breast and prostate cancers: from biology to therapy.Wide expression and significance of alternative immune checkpoint molecules, B7x and HHLA2, in PD-L1 negative human lung cancers.Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma
P2860
Q26852388-8949B5A9-BB31-49CA-A8C3-B477B45D1EECQ28743206-6A642C64-DC26-44E2-8120-99E36A245308Q34605921-90C6BAD9-EAD0-4D7B-98F3-9F16EBD2760CQ35613102-B30EB7A8-5861-4D58-858A-191CA25EEEBAQ35720116-5975429C-03A2-4056-B863-3675B348915AQ36718223-A2322B6F-5F6C-4BA7-9F41-9BF9BF13D1B1Q36932447-08002AD8-A523-4BC4-95AD-1A687268A570Q37506182-81E07209-4F69-4F4A-8F44-AC43BC4E7458Q37656365-57E60419-C99D-4574-A340-CD0378A13E4AQ37702580-AEED6ECE-F6BD-4D12-9D2C-F49E34D6A950Q37721055-55C8327C-B9DC-4FDF-83BE-993AC4FF3E29Q37889984-4BAE9C9B-3D8A-4888-8633-5FD6AED62B11Q37923993-0B75F6CC-FCC5-4A95-B9EB-4F39374A1E47Q37936540-E9B066F5-E35F-4965-BEFA-2E554DE4A306Q38089935-B914DDBD-7A8B-4376-8926-8DD7FF88215FQ39000185-449249CE-D83A-4BA8-925E-414BFFB48E86Q39210166-D0410AE0-F4BF-4B56-9FC1-93B3FD4C2AB8Q40117779-9565DBDE-664E-431B-AF8A-2CA80603003FQ40610329-80E03F6C-85EE-4421-9D49-A66F43C0B863Q42969691-87D56F1B-DCCC-4E35-86EF-8D57765FF732Q47912397-E2691EE3-39ED-4F06-9A70-A0B4FA14A973Q48158394-D1894399-F8D3-41AA-9D03-78455F1A678AQ58693796-CF5D9A2E-AE32-4E7F-AEA0-C0B324D6B4DA
P2860
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@ast
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@en
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@nl
type
label
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@ast
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@en
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@nl
prefLabel
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@ast
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@en
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@nl
P2093
P2860
P1476
T cell coinhibition in prostat ...... ays and emerging therapeutics.
@en
P2093
Jun Sik Lee
Xingxing Zang
Yael S Barach
P2860
P356
10.1016/J.MOLMED.2010.09.006
P577
2011-01-01T00:00:00Z